Trial Profile
A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SWITCH PRO
- Sponsors Novo Nordisk
- 11 Mar 2023 Results of Post Hoc Analysis assessing time in range (TIR), derived from CGM, following treatment with insulin degludec or insulin glargine U100 in patients with type 2 diabetes at risk for hypoglycemia,published in the Diabetes Therapy
- 02 Nov 2021 Puerto Rico was the planned location according to ClinicalTrials.gov record.
- 02 Nov 2021 European Union was the planned location according to European Clinical Trials Database record.